Research programme: anti-CYP1B1 antibodies - MGI Pharma Biologics

Drug Profile

Research programme: anti-CYP1B1 antibodies - MGI Pharma Biologics

Latest Information Update: 02 Apr 2007

Price : $50

At a glance

  • Originator University of Aberdeen; University of Massachusetts Medical School
  • Class Antibody diagnostics; Monoclonal antibody diagnostics
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 Dec 2004 ZYCOS has been acquired by MGI Pharma and is now called MGI Pharma Biologics
  • 16 Jul 2001 Preclinical development for Solid tumours (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top